Bill & Melinda Gates Foundation

Likarda is a biotechnology company focused on cell therapies and enabling technologies that improve delivery and function. Its Core-Shell Spherification platform encapsulates therapeutic cells in hydrogel microcapsules using biocompatible materials such as hyaluronic acid, PEG and PVA, enabling customizable formulations tailored to each therapy. The platform supports two delivery approaches: injectable, slow-release formulations that localize cells for enhanced efficacy, and immunoprotective coatings that protect cells during injection or transplantation for longer-term treatment. In addition to cell therapies, the hydrogel coating method can formulate and deliver peptides, antibodies and exosomes while preserving their activity at the target site. Likarda aims to advance therapies for diabetes and osteoarthritis, including islet-like cell delivery for diabetes and encapsulated stem cells for joint degeneration, through preclinical work in animal models.

Leinco Technologies develops and supplies high-purity monoclonal antibodies, recombinant proteins, and related reagents for diagnostics, biopharmaceutical research, and flow cytometry. The company focuses on monoclonal antibody development, in vitro production of antibodies and proteins, antibody conjugations, and associated services, including cell banking, optimization, and adaptation, to support early discovery programs and the development of protein therapeutics.

ReciBioPharm operates as a biologics company. ReciBioPharm is a division of Recipharm.

Tessera Therapeutics is an early-stage life sciences company focused on pioneering Gene Writing technology, which allows for the precise insertion of therapeutic messages into the human genome. This innovative approach aims to address diseases at their source by enabling both small and large genetic alterations. By building on recent advancements in gene therapy and gene editing, Tessera Therapeutics seeks to overcome existing limitations in these fields, enhancing their efficacy and reach. Founded by Flagship Pioneering, the company aspires to establish a new category in genetic medicine that can significantly improve patient outcomes and transform healthcare.

VitriVax is a biotechnology startup based in Boulder, Colorado, dedicated to advancing vaccine formulation through its innovative technology platform. The company has developed proprietary atomic layering thermostable antigen and adjuvant (ALTA) technology, which aims to enhance the effectiveness, affordability, and accessibility of both human and animal vaccines worldwide. This technology allows for the creation of thermostable, single-shot vaccines that can maintain or improve immune responses, enabling the incorporation of prime and booster doses in a single administration. With significant financial backing from various organizations, including the Bill and Melinda Gates Foundation, VitriVax addresses critical barriers to global vaccination, striving to improve public health outcomes.

BioSurfaces is a developer of medical devices specializing in tissue engineering and personal care products. The company leverages advanced electrospinning technology to produce nanofibrous materials that facilitate controlled drug delivery and enhance healing at the implant site. By utilizing a room-temperature electrospinning process, BioSurfaces enables the integration of drug loading within each fiber, creating a reservoir for sustained drug release. This innovative approach allows for the creation of devices and coatings as thin as 10 micrometers, making it possible to treat diseases directly at the site of implantation. The company aims to provide next-generation solutions for the medical and personal care markets, focusing on improving patient outcomes through effective disease treatment and tissue regeneration.

Freya Biosciences is a clinical-stage company specializing in women's health. It develops microbial immunotherapies, focusing on unmet needs across various indications.

La Ruche Health connects patients with virtual and at-home healthcare services via its AI-driven platform. It offers advice through text, voice, and images, facilitating easy booking of medical appointments and lab tests via iOS, Android, and WhatsApp.

AN2 Therapeutics is a biopharmaceutical company dedicated to researching, developing, and commercializing innovative medicines targeting infectious diseases. Established in 2017, the company focuses on advancing a clinical-stage antibacterial compound and has a strategic partnership with Brii Biosciences.

CanSino Biologics focuses on the R&D, manufacturing, and commercialization of vaccine products for human use. These vaccine products include pneumococcal polysaccharide and conjugate vaccines, and a DTcP-based combo, and other items. It is also dedicated to the development of new vaccine-like recombinant adenovirus vector-based tuberculosis vaccines and a recombinant protein-based pneumococcal vaccine.

Field develops pharmaceutical supply-chain technology that digitizes, modernizes, strengthens, and sustains healthcare supply chains, enabling easy access to medicines. The platform is designed to be easy to use, scalable, and effective for governments and businesses delivering healthcare worldwide, supporting improvements in how medicines reach communities and helping ensure healthcare for millions.

Eyam Vaccines and Immunotherapeutics is a life science and medical research company focused on the development of vaccines to combat infectious diseases. The company specializes in researching vaccines that target the spike glycoprotein, which is crucial for generating neutralizing antibodies against pathogens such as the novel coronavirus. Eyam employs a self-amplifying vaccine platform that enables the design of low-dose vaccines with advanced targeting capabilities, ensuring comprehensive protection, including against emerging variants. Through its innovative approach, the company aims to address pressing healthcare challenges and enhance public health outcomes.

Immorna is a biotechnology company focused on the development of RNA-based therapeutics and vaccines. The company employs various RNA platforms, including conventional, self-replicating, and circular RNA, to create innovative treatment solutions. Immorna has established a comprehensive management console that supports RNA synthesis, purification, and analytical testing, which is designed for both clinical and commercial applications. With advanced screening tools, the company has developed a range of RNA delivery vehicles, including polymers and lipid nanoparticles that utilize proprietary ionizable cationic lipids. This portfolio positions Immorna to effectively address a variety of medical needs through its cutting-edge RNA technology.

Noze specializes in digital odor perception technology, aiming to replicate the human sense of smell digitally. Utilizing advanced machine learning and an innovative sensor based on NASA technology, Noze detects and identifies odors with precision. Their primary goal is to improve patient outcomes by enabling real-time disease detection through breath-based biomarkers at any point-of-care.

Ethris GmbH is a biotechnology company based in Planegg, Germany, specializing in the development of innovative therapeutic solutions for diseases with unmet medical needs. The company has a focus on transcript therapeutics, particularly through its SNIM RNA platform, which offers a novel approach to treating various conditions by enabling the production of therapeutic proteins within the patient’s body. This platform presents an alternative to traditional recombinant protein and gene therapies, addressing a range of diseases, including rare and genetically predetermined conditions. Ethris also develops Magnetovax, a personalized tumor vaccine platform that utilizes magnetic fields for localized activation in tumors. The company has established strategic research collaborations with major pharmaceutical firms, enhancing its capabilities in regenerative medicine and therapeutic development. Founded in 2009, Ethris continues to advance its technologies to meet diverse medical needs.

Nanite is a biotechnology company focused on non-viral gene delivery through the development of programmable polymer nanoparticles. Utilizing an artificial intelligence-driven platform, Nanite integrates advanced high-throughput experimental and computational techniques to create tailored delivery vehicles capable of transporting a diverse array of genetic materials with specific targeting capabilities. This innovative approach aims to assist scientists in functional chemistry by providing therapeutically relevant solutions for gene delivery, enhancing the potential for various medical applications and indications.

Owlstone Medical develops and commercializes breathalyzers for clinical diagnostics and precision medicine. Its products detect volatile organic compounds in breath samples to diagnose diseases like lung cancer, asthma, and tuberculosis. The company has strategic collaborations with pharmaceutical companies and is based in Cambridge, UK.

Owlstone Medical develops and commercializes breathalyzers for clinical diagnostics and precision medicine. Its products detect volatile organic compounds in breath samples to diagnose diseases like lung cancer, asthma, and tuberculosis. The company has strategic collaborations with pharmaceutical companies and is based in Cambridge, UK.

Sibel Health develops wearable, clinical-grade digital health monitoring solutions for hospital and research use. The company focuses on wireless vital signs monitoring through soft, flexible sensors that are portable and user-friendly, enabling accurate data capture in clinical settings and during clinical trials. Its technology includes chest monitoring and limb sensors that measure heart rate, respiratory rate, skin temperature, body position and activity, supported by a physiological monitoring platform with analytics for both clinical care and research applications. The wearables are designed for neonatal care in the NICU as well as broader healthcare and pharmaceutical research contexts, offering biocompatible, silicone-based devices. The company aims to improve patient outcomes by providing continuous, real-time monitoring and data integration to support care decisions and study outcomes.

Corner Therapeutics is a biotechnology company focused on immunotherapy research. It specializes in developing technologies that hyperactivate dendritic cells to induce robust and durable T-cell responses, aiming to provide lifelong immunity against various cancers and infectious diseases.

Founded in 2008, Ginkgo Bioworks designs, engineers, and licenses organisms for various applications. It discovers molecules for flavors, sweeteners, cosmetics, crops, pharmaceuticals, and generates probiotic bacteria for health benefits. The company serves markets such as cultured ingredients, carbon mitigation, probiotics, and natural product discovery.

Noze specializes in digital odor perception technology, aiming to replicate the human sense of smell digitally. Utilizing advanced machine learning and an innovative sensor based on NASA technology, Noze detects and identifies odors with precision. Their primary goal is to improve patient outcomes by enabling real-time disease detection through breath-based biomarkers at any point-of-care.

LTS is a leading pharmaceutical technology company that develops and manufactures innovative drug delivery systems such as Transdermal Patches ("TTS"​) and Oral Thin Films ("OTF"​) for the pharmaceutical industry. While we continuously refine our TTS and OTF technologies further, we also research complementary Micro Array Patches for the transdermal delivery of large molecule, biological actives. Incorporated in 1984, we operate today from two sites in Andernach, Germany and West Caldwell/NJ, USA, plus representative office in Shanghai/China.

Brightseed, Inc. is a pioneering biosciences company based in San Francisco, California, founded in 2017. It specializes in the discovery of bioactive compounds in plants that have beneficial effects on human health, particularly for chronic disease management. Utilizing its proprietary Forager platform, which incorporates artificial intelligence and machine learning, Brightseed accelerates the identification and validation of these naturally occurring compounds, transforming what was once a lengthy process into a matter of months. By mapping bioactives to specific health outcomes, Brightseed provides valuable insights and science-backed solutions to partners across the consumer health continuum. The company's innovative approach aims to illuminate the connections between nature and human health, ultimately improving quality of life and addressing health challenges through the exploration of previously uncharted plant compounds.

Evotec is a drug discovery partnership firm that collaborates with pharmaceutical and biotechnology companies, academic institutions, and nonprofit organizations to advance innovative therapeutic solutions. The company specializes in a range of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. Approximately 80% of its revenue comes from shared research and development services, which involve fee-for-service work and integrated drug discovery collaborations utilizing proprietary assets. The remaining 20% of sales derive from its Just-Evotec Biologics segment, which provides contract development and manufacturing organization services for biologics. Evotec's approach emphasizes collaboration with various stakeholders, including patient advocacy groups and venture capitalists, to enhance drug discovery and development processes.

Founded in 2008, Ginkgo Bioworks designs, engineers, and licenses organisms for various applications. It discovers molecules for flavors, sweeteners, cosmetics, crops, pharmaceuticals, and generates probiotic bacteria for health benefits. The company serves markets such as cultured ingredients, carbon mitigation, probiotics, and natural product discovery.

LTS is a leading pharmaceutical technology company that develops and manufactures innovative drug delivery systems such as Transdermal Patches ("TTS"​) and Oral Thin Films ("OTF"​) for the pharmaceutical industry. While we continuously refine our TTS and OTF technologies further, we also research complementary Micro Array Patches for the transdermal delivery of large molecule, biological actives. Incorporated in 1984, we operate today from two sites in Andernach, Germany and West Caldwell/NJ, USA, plus representative office in Shanghai/China.

VitriVax is a biotechnology startup based in Boulder, Colorado, dedicated to advancing vaccine formulation through its innovative technology platform. The company has developed proprietary atomic layering thermostable antigen and adjuvant (ALTA) technology, which aims to enhance the effectiveness, affordability, and accessibility of both human and animal vaccines worldwide. This technology allows for the creation of thermostable, single-shot vaccines that can maintain or improve immune responses, enabling the incorporation of prime and booster doses in a single administration. With significant financial backing from various organizations, including the Bill and Melinda Gates Foundation, VitriVax addresses critical barriers to global vaccination, striving to improve public health outcomes.

Philips is a global technology company focused on health technology and improving people’s health and well-being through meaningful innovation. It offers a broad portfolio spanning diagnostic imaging, ultrasound, image-guided therapy, patient monitoring, health informatics, and consumer health products, as well as home care devices. The company operates across three segments—diagnosis and treatment, connected care, and personal health—and also develops lighting and consumer electronics for everyday use. Philips serves hospitals, clinics, and homes, applying advanced technologies to support prevention, diagnosis, treatment, and home-based care while pursuing sustainable, user-centered solutions.

BiomEdit discovers, designs, and develops novel probiotics and microbiome-derived bioactives using a unique platform that combines high-throughput sequencing and data analytics. Their products aim to promote animal health without antibiotics, addressing unmet needs in animal agriculture and food security.

Axmed is a business focuses on LMICs and strengthens the purchasing power of these markets to ensure the supply of cost-effective, high-quality medicines. We partner exclusively with authorized, high-quality pharmaceutical companies and certified caregivers to accelerate access to medicines.

CanSino Biologics Inc. is a biotechnology company based in Tianjin, China, focused on the research, development, manufacturing, and commercialization of vaccines. The company is actively developing a range of vaccines, including those for Ebola, meningitis, pertussis, and pneumococcal diseases, with multiple candidates currently in various phases of clinical trials. Notable products under development include the recombinant coronavirus vaccine Ad5-nCov, as well as several preclinical stage vaccines targeting adenovirus, Zika virus, meningitis, shingles, and polio. CanSino collaborates with the National Research Council of Canada to advance COVID-19 vaccine initiatives and has a co-development agreement with Precision NanoSystems to create an mRNA lipid nanoparticle vaccine against COVID-19. Founded in 2009, CanSino aims to meet the unmet medical needs in China and other emerging markets by providing high-quality vaccines at affordable prices.

AN2 Therapeutics is a biopharmaceutical company dedicated to researching, developing, and commercializing innovative medicines targeting infectious diseases. Established in 2017, the company focuses on advancing a clinical-stage antibacterial compound and has a strategic partnership with Brii Biosciences.

GE Healthcare specializes in medical technology, offering a wide range of products including medical imaging systems, information technologies, diagnostics, patient monitoring devices, and biopharmaceutical manufacturing solutions. With a global presence, they aim to enhance patient care and outcomes through innovative healthcare solutions.

The American University of Beirut (AUB) is a prominent educational institution established in 1866, originally known as Syrian Protestant College until its name change in 1920. Located in Beirut, Lebanon, AUB follows the American liberal arts model and offers a comprehensive range of programs, including bachelor's, master's, M.D., and Ph.D. degrees across six faculties: Agricultural and Food Sciences, Arts and Sciences, Engineering and Architecture, Health Sciences, Medicine, and Business. The university promotes a teaching-centered research environment and emphasizes critical thinking, personal integrity, and civic responsibility among its approximately 8,000 students. With a faculty of around 800, AUB maintains a student-faculty ratio of 11.2 to 1. The institution is accredited by the Commission on Higher Education of the Middle States Association of Colleges and Schools in the United States and has been coeducational since 1922, with a balanced student demographic of 50 percent male and 50 percent female. The primary language of instruction is English, except for courses offered in the Arabic Department and other language programs.

EHA Clinics delivers quality health care that is accessible, effective, and affordable. The company leverages technology and a skilled team to provide a superior experience, better outcomes, and lower costs for individuals, families, and businesses. Members gain seamless access to a comprehensive network that integrates routine medical care, laboratory services, pharmacies, optometry, dental care, urgent care, and specialist care. Services are available 24/7 through convenient locations, telehealth virtual visits, and home care, ensuring continuous and convenient care.

Bactolife is a company focused on addressing the global challenge of antimicrobial resistance through innovative solutions. It develops proprietary Binding Protein ingredients aimed at fortifying the gut microbiome, thereby reducing the risk of gastrointestinal infections in both humans and animals. Bactolife's platform is designed to neutralize harmful pathogens and their toxins while preserving beneficial microbes, thus promoting overall gut health. By enhancing gut microbiome modulation technologies, the company seeks to diminish reliance on traditional antimicrobials, ultimately improving health outcomes and contributing to the fight against antimicrobial resistance.

Latham BioPharm Group provides insight, knowledge, and a network to unite teams and technologies in the life sciences. It offers consulting across vaccine, therapeutic, medical device, and diagnostic product development, including business development, program management, CMC, quality, regulatory, and strategic guidance. The team averages more than 20 years of experience and includes former executives at startups and Fortune 200 companies, with some having government experience. Over more than two decades, the firm has helped clients identify, evaluate, fund, manage, and monetize opportunities in diverse segments, generating government funding and licensing investments. Its services cover strategy and portfolio analysis, market research, and commercial and government asset analysis to inform decisions and connect with target markets. It also assists in securing funding through business development and non-dilutive funding services and moves programs toward value inflection points via program management and product development teams.

Aegis Life is a biotechnology company specializing in nucleic acid delivery technology, Fusogenix PLV. With over two decades of research, they focus on accelerating the discovery, clinical development, and manufacture of vaccines and therapeutics for infectious diseases.

Hyperfine is a pioneering medical device company that developed Swoop®, the world's first FDA-cleared point-of-care MRI system. Designed to enhance patient access to critical care, Swoop produces high-quality images rapidly and at a lower cost than conventional MRIs, enabling clinicians to diagnose and treat patients swiftly in various clinical settings.

The Medicines for All Institute, operating under the auspices of the Virginia Commonwealth University School of Engineering.

Kallyope Inc. is a biotechnology company based in New York City that focuses on understanding the gut-brain axis to develop innovative therapeutics and consumer products aimed at enhancing human health. Established in 2014, Kallyope employs advanced technologies, including sequencing, computational biology, neural imaging, and human genetics, to explore gut-brain biology. The company aims to address significant unmet medical needs, such as diabetes, obesity, gut disorders, inflammatory diseases, migraines, and allergies, by creating effective and user-friendly oral agents. Kallyope's team consists of experienced scientists from leading institutions, working alongside a skilled team with a strong track record in drug discovery and development. Through its research, Kallyope seeks to deliver transformative solutions that improve overall health outcomes.

Vir Biotechnology, Inc. is a clinical-stage immunology company based in San Francisco, California, founded in 2016. It specializes in developing innovative therapeutic products aimed at treating and preventing serious infectious diseases. The company's pipeline includes several promising candidates, such as VIR-2218 and VIR-3434 for hepatitis B, VIR-2482 for influenza A, VIR-1111 for HIV, and VIR-2020 for tuberculosis. Vir Biotechnology employs advanced technologies and scientific expertise to manipulate immune responses and enhance pathogen-host interactions. The company has established various collaborations and agreements with notable organizations, including the Bill & Melinda Gates Foundation, National Institutes of Health, and Alnylam Pharmaceuticals, among others. Additionally, it has a manufacturing agreement with Samsung Biologics for the production of SARS-CoV-2 antibodies aimed at potential COVID-19 treatment. Through its innovative approaches, Vir Biotechnology aspires to significantly reduce the burden of infectious diseases in the future.

Audere is a digital health nonprofit developing software to improve global health in underserved communities.

Smart Immune is a clinical‑stage biotechnology company developing next‑generation hematopoietic stem cell–based biotherapies to improve outcomes for patients with severe diseases. Its flagship program uses T‑cell progenitors (ProTcells) to enable rapid, polyclonal, and safe immune reconstitution after transplantation. The platform integrates targeted conditioning, gene therapy, and genome editing to extend treatment options for inherited blood disorders, blood cancers, and other life‑threatening conditions.

Evotec is a drug discovery partnership firm that collaborates with pharmaceutical and biotechnology companies, academic institutions, and nonprofit organizations to advance innovative therapeutic solutions. The company specializes in a range of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. Approximately 80% of its revenue comes from shared research and development services, which involve fee-for-service work and integrated drug discovery collaborations utilizing proprietary assets. The remaining 20% of sales derive from its Just-Evotec Biologics segment, which provides contract development and manufacturing organization services for biologics. Evotec's approach emphasizes collaboration with various stakeholders, including patient advocacy groups and venture capitalists, to enhance drug discovery and development processes.

Noze specializes in digital odor perception technology, aiming to replicate the human sense of smell digitally. Utilizing advanced machine learning and an innovative sensor based on NASA technology, Noze detects and identifies odors with precision. Their primary goal is to improve patient outcomes by enabling real-time disease detection through breath-based biomarkers at any point-of-care.

UW Medicine is a clinical research and healthcare system that provides a higher degree of healthcare for pre-med students. UW Medicine health professionals provide the most up-to-date care for each individual patient through these integrated programs, lead one of the world's largest and most comprehensive medical research programs, and provide innovative learning programs for students, trainees, and practitioners in the health professions. UW Medicine, as the region's only comprehensive clinical, research, and learning health system, provides a higher level of healthcare, ranging from primary and preventive care to the most highly specialized care for the most complex medical conditions.

VisualDx is a diagnostic clinical decision support system that aims to enhance diagnostic accuracy and improve patient safety. By integrating a curated medical image library with a powerful search engine, VisualDx provides clinicians with patient-specific answers in seconds. The platform is designed for both web-based and mobile use, facilitating point-of-care decisions and fostering patient engagement. It offers high-quality images that encompass a wide range of pediatric and adult medical conditions. VisualDx is utilized by over 2,300 hospitals, clinics, and medical schools globally, enabling healthcare professionals to make better and faster decisions for their patients.

LumiraDx Ltd, incorporated in 2016 and based in London, United Kingdom, is a next-generation point-of-care diagnostics company. It specializes in manufacturing an innovative diagnostic platform that provides a wide range of tests with lab-comparable performance. LumiraDx aims to transform healthcare by offering solutions that facilitate integrated, patient-centered care, enhancing safety, efficiency, and health outcomes. The company's diagnostic system includes a portable instrument, low-cost test strips, and seamless digital connectivity, making diagnostic-led care simpler and more accessible. LumiraDx operates in multiple countries, including the United States, Italy, Germany, and Sweden, with a significant portion of its revenue generated from the U.S. market.

Aspen Pharmacare is a global pharmaceutical company that manufactures and supplies branded, generic, and specialty medicines across over 150 countries. Its portfolio includes general anaesthetics, muscle relaxants, anticoagulants, and other therapeutic areas. Aspen also offers contract manufacturing services for active pharmaceutical ingredients and finished dose forms.

Touchlight Genetics Ltd. is a biotechnology company based in Leatherhead, United Kingdom, specializing in DNA therapies and technology. Founded in 2007, the company has developed the proTL synthetic DNA platform, which enables the production of closed linear DNA, known as doggybone DNA, without the need for bacterial fermentation. This innovative platform is designed for various applications, including veterinary vaccines, monoclonal antibodies, cancer and gene therapies, allergy treatments, RNA interference therapies, and stem cell reprogramming. Touchlight Genetics is led by a team with significant expertise in life sciences, including founder and CEO Jonny Ohlson and Non-Executive Chairman Clive Dix. The company has successfully established collaborations with prominent academic institutions such as Imperial College London and the University of Pennsylvania, enhancing its research capabilities and expanding its impact in the field of DNA vaccine development for oncology and infectious diseases.

Daré Bioscience is a healthcare company committed to the development and commercialization of innovative products in women’s reproductive health.

Contro is an online platform offering a convenient subscription service for sexual health products such as birth control and erectile dysfunction treatment. Through secure digital consultations with doctors, Contro provides prescriptions and delivers medications discreetly to customers' doorsteps in South Africa. The service offers flexibility with its cancel anytime policy.

Bayer is a global life science company specializing in healthcare and agriculture. It focuses on developing and commercializing products and solutions based on scientific knowledge, with core competencies in pharmaceuticals, consumer health, and crop science.

Helium Health specializes in digitizing healthcare systems in Africa. It offers software tools for hospitals and clinics to manage patient health records, operations, and telemedicine. The company aims to create the largest healthcare data exchange in Africa.

CQUIN is made up of representatives from ministries of health, implementing partners, civil society, associations of people living with HIV, academic institutions, and donor agencies that work with CQUIN to scale up DSD according to each country’s unique needs. The company encourages experience sharing, peer-to-peer learning, and collaborative issue solving. It allows member countries to obtain technical support from Columbia University's ICAP.

Bactolife is a company focused on addressing the global challenge of antimicrobial resistance through innovative solutions. It develops proprietary Binding Protein ingredients aimed at fortifying the gut microbiome, thereby reducing the risk of gastrointestinal infections in both humans and animals. Bactolife's platform is designed to neutralize harmful pathogens and their toxins while preserving beneficial microbes, thus promoting overall gut health. By enhancing gut microbiome modulation technologies, the company seeks to diminish reliance on traditional antimicrobials, ultimately improving health outcomes and contributing to the fight against antimicrobial resistance.

CaliberMRI is a platform that includes brain, breast, prostate, and custom phantoms, and companion automated quality control software. They provide services that include quantitative MRI, qmri, phantoms, quantitative medicine, radiology, breast cancer, and calibration.

Eleven Therapeutics is a biotechnology company pioneering AI-driven medicinal nucleic acids. It specializes in developing extended durability mRNA therapeutics, targeting unmet medical needs in metabolic, endocrinologic, and infectious diseases.

Iconovo is a Swedish device company that designs and licenses inhalation devices for pharmaceutical use. It develops multiple dry powder inhaler platforms, including a reservoir-based system, a capsule-based system, a unit-dose platform, and a pre-metered option, and it provides customized inhalation solutions to support both generic and innovative drug development. Founded in 2013 and headquartered in Lund, Iconovo collaborates with international pharmaceutical companies to advance inhaled medicines for respiratory conditions and other therapies. Its technology emphasizes safety, user-friendly design, and cost efficiency, with the aim of enabling development and commercialization of novel pharmaceuticals and vaccines and extending opportunities around patent expirations for established products. By offering protected inhaler technologies and development services, Iconovo seeks to serve customers across global markets.

Sapient enables the discovery of circulating small molecule biomarkers at unprecedented speed and scale. Leveraging next-generation mass spectrometry, biocomputational analysis, and large-scale human biology databases, its platform supports the rapid identification and validation of circulating biomarkers of health, disease, and drug response which are needed to align patients, disease biology, and specific therapies.

Flywheel.io is a cloud-based data management platform tailored for biomedical research and collaboration. Founded in 2012 and headquartered in Minneapolis, Minnesota, the company provides a suite of tools designed to enhance the workflow of scientists and researchers. Its platform supports medical imaging, scientific computation, and content management, enabling users to capture, manage, and analyze research data efficiently. By utilizing cloud scalability and automation, Flywheel facilitates collaborative research, machine learning applications, and multicenter studies, which help organizations streamline their research processes. The platform, featuring a modern web interface and extensible compute engine, aims to eliminate bottlenecks in innovation, allowing researchers to focus on scientific discovery rather than IT challenges.

SwipeRx is a digital platform designed for pharmacies that connects pharmaceutical manufacturers, pharmacies, and patients. It offers specialized healthcare logistics, negotiated pricing, and financing solutions, creating the largest digital pharmacy purchasing network. The platform generates insights that enhance collaboration among pharmacies, improve pharmacist education, and strengthen market access. Additionally, it optimizes commercial strategies and boosts operational efficiencies, providing real-time access to patient and sales data. By doing so, SwipeRx enables its clients to improve patient affordability, access, and adherence to medications.

Cardea Bio, Inc. is a biotechnology company based in San Diego, California, focused on developing and commercializing bioelectronics for research and diagnostics. Established in 2013, Cardea utilizes proprietary graphene-based digital biosensors to create advanced biosensor hardware, software, and molecular infrastructure, enabling precision healthcare through improved diagnostic capabilities. The company's product offerings include the AGILE R100, an innovative assay for drug discovery, and the AGILE R200, an automated high-throughput screening solution. Cardea's biosensors convert biomolecular interactions into digital data, allowing for real-time biological signal analysis and access to streaming multi-omics data. Their solutions cater to various applications in life sciences and healthcare, such as small molecule validation, antibody characterization, and biomolecular analysis.

Yemaachi Biotechnology employs advanced immunogenomics, bioinformatics, and artificial intelligence to expedite the development of cancer detection and treatment strategies, aiming to reduce the economic impact of cancer.

Butterfly Network is a medical technology company developing handheld ultrasound systems that aim to democratize imaging and expand access to care. Its flagship device, a single-probe handheld system powered by Ultrasound-on-Chip semiconductor technology, enables whole-body diagnostic imaging with cloud-connected software and a mobile application, allowing clinicians to acquire, store, and analyze ultrasound data in real time. The platform supports workflow integration for hospitals and outpatient settings, and can image vascular, cardiac, abdominal, urological, fetal, gynecological, and musculoskeletal regions. The company envisions improving early detection and remote management of health conditions by enabling pocket-sized imaging capability and scalable ultrasound programs across healthcare facilities. Butterfly Network was founded with a mission to advance global health equity by increasing ultrasound access worldwide. The technology combines a compact hardware device with software to streamline acquisition, interpretation, and sharing of ultrasound information in clinical workflows.

Particles for Humanity is a company dedicated to transforming early-stage medical technologies into practical products aimed at improving the quality of life for individuals in low-resource settings. The company focuses on developing a portfolio of healthcare solutions that address critical issues such as vaccination and malnutrition. By employing a rigorous product development process that incorporates input from end-users, Particles for Humanity aims to create financially sustainable products that meet the specific needs of underserved populations. Through its innovative approach, the company seeks to empower individuals to combat serious health challenges and enhance their overall well-being.

Evotec is a drug discovery partnership firm that collaborates with pharmaceutical and biotechnology companies, academic institutions, and nonprofit organizations to advance innovative therapeutic solutions. The company specializes in a range of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. Approximately 80% of its revenue comes from shared research and development services, which involve fee-for-service work and integrated drug discovery collaborations utilizing proprietary assets. The remaining 20% of sales derive from its Just-Evotec Biologics segment, which provides contract development and manufacturing organization services for biologics. Evotec's approach emphasizes collaboration with various stakeholders, including patient advocacy groups and venture capitalists, to enhance drug discovery and development processes.

Elarex, a Canadian healthcare technology company, specializes in developing and commercializing proprietary formulation technologies. Its flagship innovation, PT120, stabilizes biologicals, including live vaccines, enabling them to maintain full efficacy even when stored at 40°C, comparable to -80°C storage. This breakthrough allows for broader access to vaccines and biological drugs by facilitating transportation and storage in diverse environments, thereby enhancing global healthcare accessibility.

Providence Therapeutics is a Toronto-based biotechnology company focused on messenger RNA vaccine therapies, including personalized cancer vaccines that target tumor mutations and vaccines for infectious diseases such as COVID-19, delivered via lipid nanoparticles. It concentrates on oncology research, drug product development, and vaccine manufacturing, leveraging its expertise in mRNA to develop targeted treatments. Founded in 2015, Providence Therapeutics aims to advance medicines for diseases with unmet medical needs.

Mydawa operates an online pharmacy platform that connects patients directly with drug stores. It offers a wide range of high-quality medicines and wellness products, enabling consumers to purchase these affordably and conveniently via their mobile phones.

Philips is a global technology company focused on health technology and improving people’s health and well-being through meaningful innovation. It offers a broad portfolio spanning diagnostic imaging, ultrasound, image-guided therapy, patient monitoring, health informatics, and consumer health products, as well as home care devices. The company operates across three segments—diagnosis and treatment, connected care, and personal health—and also develops lighting and consumer electronics for everyday use. Philips serves hospitals, clinics, and homes, applying advanced technologies to support prevention, diagnosis, treatment, and home-based care while pursuing sustainable, user-centered solutions.

Inventprise is a biotechnology company focused on the development of GMP vaccines, particularly a 25-valent pneumococcal conjugate vaccine (PCV). Founded in 2012 and based in Redmond, Washington, the company aims to provide large-scale vaccine supplies to low- and middle-income countries, significantly supported by funding from the Bill and Melinda Gates Foundation. In addition to its vaccine development efforts, Inventprise offers comprehensive outsourcing solutions for biopharmaceutical manufacturing, which include quality control assays, batch records, and necessary documentation. The company also provides in-person training and operates a fully equipped quality control laboratory for testing vaccine identity, potency, purity, and stability, thereby addressing health inequalities and promoting healthier lives globally.

Brightseed, Inc. is a pioneering biosciences company based in San Francisco, California, founded in 2017. It specializes in the discovery of bioactive compounds in plants that have beneficial effects on human health, particularly for chronic disease management. Utilizing its proprietary Forager platform, which incorporates artificial intelligence and machine learning, Brightseed accelerates the identification and validation of these naturally occurring compounds, transforming what was once a lengthy process into a matter of months. By mapping bioactives to specific health outcomes, Brightseed provides valuable insights and science-backed solutions to partners across the consumer health continuum. The company's innovative approach aims to illuminate the connections between nature and human health, ultimately improving quality of life and addressing health challenges through the exploration of previously uncharted plant compounds.

Titan Pharmaceuticals, Inc. is a biopharmaceutical company based in South San Francisco, California, focused on developing proprietary therapeutics for chronic diseases. The company utilizes its innovative ProNeura technology, a long-term drug delivery platform, to create products that maintain stable blood levels of medication over extended periods. Titan's principal product, Probuphine, is the first slow-release implant formulation of buprenorphine, designed for the outpatient treatment of opioid dependence. This implant allows for consistent medication delivery for up to six months, enhancing patient compliance and reducing the risk of misuse associated with traditional sublingual formulations. Additionally, Titan is developing ProNeura-Ropinirole, an implant for treating Parkinson’s disease, and a triiodothyronine implant for hypothyroidism. Established in 1992, Titan is committed to addressing serious medical disorders through its advanced drug delivery solutions.

Eleven Therapeutics is a biotechnology company pioneering AI-driven medicinal nucleic acids. It specializes in developing extended durability mRNA therapeutics, targeting unmet medical needs in metabolic, endocrinologic, and infectious diseases.

Sunflower Therapeutics is a biotechnology company specializing in next-generation protein manufacturing solutions. It aims to enhance global patient access to biological medicines by developing and implementing advanced technologies that benefit worldwide populations. The company employs strain engineering, integrated process development, and automated multi-product facilities to create efficient and scalable production methods.

CRISPR Therapeutics specializes in developing transformative gene-based medicines using its proprietary CRISPR/Cas9 gene-editing platform. This technology enables precise, directed changes to genomic DNA for treating serious human diseases. The company focuses on various disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases.

Particles for Humanity is a company dedicated to transforming early-stage medical technologies into practical products aimed at improving the quality of life for individuals in low-resource settings. The company focuses on developing a portfolio of healthcare solutions that address critical issues such as vaccination and malnutrition. By employing a rigorous product development process that incorporates input from end-users, Particles for Humanity aims to create financially sustainable products that meet the specific needs of underserved populations. Through its innovative approach, the company seeks to empower individuals to combat serious health challenges and enhance their overall well-being.

Icosavax develops virus-like particle (VLP) vaccines using its proprietary computational design platform. Its primary focus is creating vaccines for life-threatening respiratory diseases, with current candidates targeting respiratory syncytial virus (RSV), human metapneumovirus (hMPV), and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Founded in 2017, the company aims to discover, develop, and commercialize vaccines against infectious diseases.

Ilara Health develops and distributes AI-powered diagnostic devices for primary care doctors serving rural and peri-urban communities in Africa, with its headquarters in Nairobi, Kenya. The compact devices connect to a proprietary software platform and electronic medical records, recording patient data to support accurate, affordable diagnostics at the point of care. The company aims to expand access to essential diagnostics by targeting the highly fragmented primary care infrastructure and delivering devices directly to clinicians, enabling clinicians to deliver timely, data-backed diagnostic services.

Evotec is a drug discovery partnership firm that collaborates with pharmaceutical and biotechnology companies, academic institutions, and nonprofit organizations to advance innovative therapeutic solutions. The company specializes in a range of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. Approximately 80% of its revenue comes from shared research and development services, which involve fee-for-service work and integrated drug discovery collaborations utilizing proprietary assets. The remaining 20% of sales derive from its Just-Evotec Biologics segment, which provides contract development and manufacturing organization services for biologics. Evotec's approach emphasizes collaboration with various stakeholders, including patient advocacy groups and venture capitalists, to enhance drug discovery and development processes.

Daré Bioscience is a healthcare company committed to the development and commercialization of innovative products in women’s reproductive health.

Sapient enables the discovery of circulating small molecule biomarkers at unprecedented speed and scale. Leveraging next-generation mass spectrometry, biocomputational analysis, and large-scale human biology databases, its platform supports the rapid identification and validation of circulating biomarkers of health, disease, and drug response which are needed to align patients, disease biology, and specific therapies.

HJF Medical Research International is an NGO that supports international programs advancing medical research and HIV prevention.

Daré Bioscience is a healthcare company committed to the development and commercialization of innovative products in women’s reproductive health.

Montreal Heart Institute is a specialty hospital dedicated to the development of cardiology.

Particles for Humanity is a company dedicated to transforming early-stage medical technologies into practical products aimed at improving the quality of life for individuals in low-resource settings. The company focuses on developing a portfolio of healthcare solutions that address critical issues such as vaccination and malnutrition. By employing a rigorous product development process that incorporates input from end-users, Particles for Humanity aims to create financially sustainable products that meet the specific needs of underserved populations. Through its innovative approach, the company seeks to empower individuals to combat serious health challenges and enhance their overall well-being.

Vaxxas is a biotechnology company developing needle-free vaccination technology. It uses proprietary dry-coating technology to eliminate or significantly reduce the need for vaccine refrigeration, easing storage and transportation logistics.

Inovio Pharmaceuticals specializes in developing DNA medicines to treat, prevent, and protect against diseases caused by human papillomavirus (HPV), cancer, and infectious pathogens. Its proprietary SynCon immunotherapy platform enables robust immune responses via direct intracellular delivery using a smart device. The company's lead candidate, VGX-3100, has shown promise in clinical trials for treating precancerous cervical dysplasia.

Centre for Innovation in Regulatory Science is a neutral, independently managed UK-based subsidiary company, forming part of the Clarivate Analytics group. CIRS provides an international forum for industry, regulators, HTA and other healthcare stakeholders to meet, debate and develop regulatory and reimbursement policy through the innovative application of regulatory science and to facilitate access to medical products. This is CIRS’ purpose. CIRS is operated solely for promotion of its purpose. The organisation has its own dedicated management and advisory boards, and its funding is derived from membership dues, related activities, special projects and grants.

Immunocore is a biotechnology company focused on developing novel T cell receptor-based therapies to treat diseases with high unmet needs, such as cancer and viral infections. Its proprietary platform enables the creation of bispecific immunotherapies, with IMCgp100 being its lead clinical candidate for metastatic melanoma.

Biological Dynamics Inc. is a healthcare company based in San Diego, California, that specializes in developing a proprietary technology platform for the direct and selective capture of large necrotic particles from physiological solutions such as whole blood, serum, and plasma. This platform facilitates the detection of diseases, particularly cancers, in their earliest stages by enabling access to native-state biomarkers and nanoparticles for multiomics applications. The company offers various products and services, including the TR(ACE) Assay for monitoring treatment responses in cancer, tissue-based molecular and cfDNA liquid biopsy testing for personalized medicine, and a biomarkers program aimed at drug development for Alzheimer's disease. Additionally, Biological Dynamics provides clinical laboratory services, including molecular and next-generation sequencing, and supports applications in autoimmune diseases, transplant rejection, and traumatic brain injury. Founded in 2008, the company is dedicated to improving global health outcomes through innovative diagnostic solutions.

Macro-Eyes, Inc. is a machine learning company focused on enhancing access to healthcare through its innovative solutions. Its primary product, Sibyl, employs artificial intelligence for intelligent patient scheduling, which has shown a capability to improve patient utilization by 15%, enabling healthcare providers to see more patients without extending clinical hours. This technology is built on extensive research and deployment of AI for clinical decision support at prominent institutions, including Stanford University and major health systems in the United States. The company has garnered support from the Bill & Melinda Gates Foundation to develop a predictive supply chain for health, aimed at optimizing resource allocation at individual health facilities and pharmacies to prevent stock-outs and reduce waste. Additionally, Macro-Eyes is collaborating with the California Primary Care Association to implement Sibyl across 1,800 health facilities, thereby furthering its mission to increase access to life-saving care.

VisualDx is a diagnostic clinical decision support system that aims to enhance diagnostic accuracy and improve patient safety. By integrating a curated medical image library with a powerful search engine, VisualDx provides clinicians with patient-specific answers in seconds. The platform is designed for both web-based and mobile use, facilitating point-of-care decisions and fostering patient engagement. It offers high-quality images that encompass a wide range of pediatric and adult medical conditions. VisualDx is utilized by over 2,300 hospitals, clinics, and medical schools globally, enabling healthcare professionals to make better and faster decisions for their patients.

1mg is an Indian digital healthcare platform, launched in 2015, that operates from Gurgaon, Haryana. It aims to make healthcare more accessible, understandable, and affordable. The platform enables users to find detailed information about prescribed medicines, buy them, and search for drugs based on ailments, classes, companies, and brands. Additionally, 1mg offers a doctor platform to help users find suitable healthcare professionals and a diagnostics service for transparent and cost-effective lab tests. The company empowers consumers and caregivers to choose the most appropriate healthcare services at competitive prices.

Landcent is a company dedicated to combating global infectious diseases, with a focus on malaria. It develops and delivers affordable, sustainable solutions that are safe for large-scale use, aiming to accelerate the fight against these diseases and ultimately eliminate them.

MedinCell S.A. is a pharmaceutical company focused on developing innovative therapeutic solutions through its proprietary BEPO technology, which facilitates long-acting injectable products utilizing biodegradable polymers and a biocompatible solvent. Based in Jacou, France, the company is engaged in ongoing research and development to optimize the efficiency and accessibility of medical treatments across various therapeutic areas. MedinCell's product pipeline includes several candidates, such as mdc-IRM, a subcutaneous injection for schizophrenia currently in Phase III trials, and mdc-CWM, an intra-articular injection aimed at treating pain and inflammation. Additionally, the company is exploring formulations like mdc-WWM for contraception and mdc-ANG for central nervous system disorders, alongside other candidates targeting pain management and organ transplant applications. Through its advancements in controlled, long-acting injectables, MedinCell aims to enhance treatment outcomes for patients.

RJH Biosciences is a biotechnology company dedicated to the development of transfection reagents and delivery agents for nucleic acids. It focuses on creating innovative systems that effectively transport various types of nucleic acids to human cells and cell lines, particularly targeting blood cancers and the modification of immune cells. By advancing these technologies, RJH Biosciences aims to enable healthcare professionals to harness the therapeutic potential of nucleic acids, ultimately contributing to the development of new medical treatments. The company distributes its products through its website and engages in projects that further enhance its offerings in the field of biotechnology.